Amgen Inc said that its oncolytic virus product, talimogene laherparepvec (TVEC), reduced the size of tumours in patients with metastatic melanoma during a recent Phase 3 trial. The data comes from a retrospective analysis of nearly 4,000 tumour lesions.
